For the quarter ending 2025-09-30, XENE had -$30,867K decrease in cash & cash equivalents over the period. -$72,033K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -90,896 | -149,753 |
| Interest receivable and accretion of discounts on marketable securities | -177 | -6,505 |
| Depreciation of property plant and equipment | 641 | 1,291 |
| Non-cash operating lease expense | 330 | 649 |
| Deferred income tax recovery | -701 | -1,383 |
| Stock-based compensation | 13,705 | 25,887 |
| Unrealized foreign exchange (gain) loss | 60 | 28 |
| Realized loss on marketable securities | -89 | -518 |
| Other receivables | -283 | -380 |
| Prepaid expenses and other current assets | 3,373 | 6,412 |
| Accounts payable and accrued liabilities | 5,232 | -2,914 |
| Operating lease liability | -337 | -625 |
| Other liabilities | 3,158 | - |
| Net cash used in operating activities | -71,752 | -125,885 |
| Purchases of property, plant and equipment | 281 | 200 |
| Purchases of marketable securities | 74,702 | 220,055 |
| Proceeds from marketable securities | 113,514 | 337,025 |
| Net cash provided by investing activities | 38,531 | 116,770 |
| Net cash provided by financing activities | 2,360 | 1,216 |
| Effect of exchange rate changes on cash and cash equivalents | -6 | 568 |
| Decrease in cash and cash equivalents | -30,867 | -7,331 |
| Cash and cash equivalents at beginning of period | 142,712 | - |
| Cash and cash equivalents at end of period | 104,514 | - |
Xenon Pharmaceuticals Inc. (XENE)
Xenon Pharmaceuticals Inc. (XENE)